Rohlik Q T, Adams D, Kull F C, Jacobs S
Burroughs Wellcome Co., Research Triangle Park, N. C. 27709.
Biochem Biophys Res Commun. 1987 Nov 30;149(1):276-81. doi: 10.1016/0006-291x(87)91635-4.
Alpha IR-3, a monoclonal antibody to the insulin-like growth factor I receptor which blocks insulin-like growth factor I binding and inhibits its activity, inhibits the binding of 125I-insulin-like growth factor I to MCF-7 cells (an estrogen dependent human breast carcinoma cell line) with an IC-50 of approximately 100 ng/ml. It also inhibits the growth of MCF-7 cells cultured in 5% calf serum with approximately the same IC-50. Inhibition of growth occurs both when cells are cultured in the presence and absence of estrogen and is more pronounced when cells are grown at a low density. These findings demonstrate a requirement for insulin-like growth factor I for optimal growth of MCF-7 cells and suggest that it is an autocrine growth factor in these cells.
αIR-3是一种针对胰岛素样生长因子I受体的单克隆抗体,它能阻断胰岛素样生长因子I的结合并抑制其活性,以约100 ng/ml的半数抑制浓度(IC-50)抑制125I-胰岛素样生长因子I与MCF-7细胞(一种雌激素依赖性人乳腺癌细胞系)的结合。它还以大致相同的IC-50抑制在5%小牛血清中培养的MCF-7细胞的生长。无论细胞在有雌激素还是无雌激素的情况下培养,生长均受到抑制,且当细胞低密度生长时抑制更为明显。这些发现表明MCF-7细胞的最佳生长需要胰岛素样生长因子I,并提示它是这些细胞中的一种自分泌生长因子。